They are not zombies, they are fallen angels.” That is view of Nick Johnston, a U.K-based banker who has come up with a new ...

In all practicality, U.S. FDA Commissioner Marty Makary’s recently announced policy directive removing industry ...

Bioxodes SA is gearing up fundraising for a follow-up study to the newly released interim phase IIa results of its lead asset in treating intracerebral hemorrhagic stroke. Data from the first 16 ...

Synthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC) space, began with its founders ...

Growth in the first quarter for Boston Scientific Corp.’s blockbuster products, Farapulse and Watchman, pushed the company well over analysts’ expectations and gave management confidence to raise its ...

The BioWorld Biopharmaceutical Index reached a first quarter (Q1) peak of 9.64% by the end of February, before closing March ...

Just simply getting old, from age 50 to 75, increased risk for Alzheimer’s disease by 100-fold, which really dwarfed 10-fold increase in risk, conferred by all known risk factors combined, including ...

AMT Medical BV raised $25 million in a series B financing round for its Excimer Laser Assisted Non-Occlusive Anastomosis ...

Named after Swiss mountains, Granite Bio AG emerged from stealth with $70 million in funds through a series B to advance two ...

Regulatory reliance is all the rage of late, but some nations employ a four-tier risk classification scheme while others use a three-tier scheme.

The U.S. FDA’s authority to require cybersecurity measures in premarket submissions is a radical change for industry, but firms must document that they have erected solid cybersecurity measures.

Mesenchymal stem cells (MSCs) have long been recognized for their potential in cancer therapy. However, the effectiveness of MSCs in cancer treatment has been hampered by their limited tumor-homing ...